Acrobiosystems for English
icon_bulk_orderAnfrage Sammelbestellung/Schnellbestellung
user
  1. Übersicht
  2. Mein Profil
  3. Meine Adresse
  4. Meine Bestellungen
  5. Acro-Mitgliedschaft
Login Registrieren
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
0
Es befinden sich keine Waren im Warenkorb !
Mein Warenkorb|Check Out
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > PD-L1

PD-L1

Brief Information

Name:Programmed death-ligand 1
Target Synonym:HPD-L1,Programmed Cell Death 1 Ligand 1,PDCD1L1,B7H1,PDL1,Programmed Death Ligand 1,B7-H1,B7-H,B7-H1 Antigen,CD274,B7 homolog 1,PDCD1 ligand 1,PD-L1,PDCD1LG1,CD274 Molecule,CD274 Antigen
Number of Launched Drugs:7
Number of Drugs in Clinical Trials:156
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Product> Filter Results
Nach Produktstatus:
Nach Produktkategorie :
Nach Arten:
Nach Markierungen:
Nach Konjugaten:
Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
PD1-HP2H3 Human PE-Labeled Human PD-L1 / B7-H1 (19-238) Protein, His TagStar Staining
PD1-H5213 Human Human PD-L1 / B7-H1 Protein, Tag Free (MALS verified)
PD1-H5213-structure
PD1-H5213-sds
PD1-C82F3 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, Fc,Avitag™ (MALS verified)
PD1-C82F3-structure
PD1-C82F3-sds
PDL-M82E7 Mouse Biotinylated Mouse PD-L1 / B7-H1 Protein, His,Avitag™ (MALS verified)
PDL-M82E7-structure
PDL-M82E7-sds
HCS-S240 Rabbit Recombinant Monoclonal Anti-PD-L1 Antibody, Rabbit (5D3)
EP-157 Mouse Mouse PD-L1 : Mouse PD-1 [Biotinylated] Inhibitor Screening ELISA Kit
SCCHO-ATP077M Human CHO/Human PD-L1 Stable Cell Line (Medium Expression) Development Service
SCCHO-ATP077H Human CHO/Human PD-L1 Stable Cell Line (High Expression) Development Service
SCCHO-ATP077L Human CHO/Human PD-L1 Stable Cell Line (Low Expression) Development Service
SCRAJ-STT075 Human Raji/Human PD-L1 Stable Cell Line Development Service
EP-133 Human PD-L1 : PD-1 [Biotinylated] Inhibitor Screening ELISA Kit
PDL-C82E8 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, His,Avitag™ (MALS verified)
PDL-C82E8-structure
PDL-C82E8-sds
PDL-C52H4 Canine Canine PD-L1 / B7-H1 Protein, His Tag (MALS verified)
PDL-C52H4-structure
PDL-C52H4-sds
PD1-H82A3 Human Biotinylated Human PD-L1 / B7-H1 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
PD1-H82A3-structure
PD1-H82A3-sds
PD1-H52H3 Human Human PD-L1 / B7-H1 (19-134) Protein, His Tag (MALS verified)
PD1-H52H3-structure
PD1-H52H3-sds
PD1-C52H3 Canine Canine PD-L1 / B7-H1 Protein, Fc Tag
PD1-C52H3-structure
PD1-C52H3-sds
PDL-H82E4 Human Biotinylated Human PD-L1 / B7-H1 (19-134) Protein, His,Avitag™ (recommended for biopanning) (MALS verified)
PDL-H82E4-structure
PDL-H82E4-sds
PDL-R52H6 Rabbit Rabbit PD-L1 / B7-H1 Protein, His Tag (MALS verified)
PDL-R52H6-structure
PDL-R52H6-sds
PDL-H5250 Human Human PD-L1 / B7-H1 Protein, Llama IgG2b Fc Tag, low endotoxin (MALS verified)
PDL-H5250-structure
PDL-H5250-sds
PDL-H82F2 Human Biotinylated Human PD-L1 / B7-H1 Protein, Fc,Avitag™ (MALS verified)
PDL-H82F2-structure
PDL-H82F2-sds
PD1-M52A2 Mouse Mouse PD-L1 / B7-H1 Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)
PD1-M52A2-structure
PD1-M52A2-sds
PD1-H82E5 Human Biotinylated Human PD-L1 / B7-H1 Protein, Avitag™,His Tag (MALS verified)
PD1-H82E5-structure
PD1-H82E5-sds
PD1-M82F5 Mouse Biotinylated Mouse PD-L1 / B7-H1 Protein, Fc,Avitag™ (MALS verified)
PD1-M82F5-structure
PD1-M82F5-sds
PD1-M5220 Mouse Mouse PD-L1 / B7-H1 Protein, His Tag (MALS verified)
PD1-M5220-structure
PD1-M5220-sds
PD1-M5251 Mouse Mouse PD-L1 / B7-H1 Protein, Fc Tag (MALS verified)
PD1-M5251-structure
PD1-M5251-sds
PD1-H52A3 Human Human PD-L1 / B7-H1 Protein, Mouse IgG1 Fc Tag, low endotoxin (MALS verified)
PD1-H52A3-structure
PD1-H52A3-sds
PD1-C52H4 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, His Tag (MALS verified)
PD1-C52H4-structure
PD1-C52H4-sds
PD1-C5253 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, Fc Tag (MALS verified)
PD1-C5253-structure
PD1-C5253-sds
PD1-H82F3 Human Biotinylated Human PD-L1 / B7-H1 Protein, Fc,Avitag™,His Tag (MALS verified)
PD1-H82F3-structure
PD1-H82F3-sds
PD1-H5282 Human Human PD-L1 / B7-H1 Protein, Twin-Strep Tag (HPLC verified)
PD1-H5282-structure
PD1-H5282-sds
PD1-H5282-hplc
PD1-H5258 Human Human PD-L1 / B7-H1 Protein, Fc Tag (MALS verified)
PD1-H5258-structure
PD1-H5258-sds
PD1-H5229 Human Human PD-L1 / B7-H1 Protein, His Tag (MALS verified)
PD1-H5229-structure
PD1-H5229-sds
ACRO Quality

Part of Bioactivity data

SCCHO-ATP077M-Cell-based assay
PD-L1 FACS

Expression analysis of human PD-L1 on CHO/ Human PD-L1 Stable Cell Line by FACS.
Cell surface staining using PE-labeled anti-human PD-L1 antibody was performed on CHO/Human PD-L1 Stable Cell Line with different expression levels: CHO/Human PD-L1 Stable Cell Line (Low Expression); CHO/Human PD-L1 Stable Cell Line (Medium Expression); CHO/Human PD-L1 Stable Cell Line (High Expression).

Protocol
SCCHO-ATP077H-Cell-based assay
PD-L1 FACS

Expression analysis of human PD-L1 on CHO/ Human PD-L1 Stable Cell Line by FACS.
Cell surface staining using PE-labeled anti-human PD-L1 antibody was performed on CHO/Human PD-L1 Stable Cell Line with different expression levels: CHO/Human PD-L1 Stable Cell Line (Low Expression); CHO/Human PD-L1 Stable Cell Line (Medium Expression); CHO/Human PD-L1 Stable Cell Line (High Expression).

Protocol
PD1-C82F3-SPR
PD-L1 SPR

Biotinylated Cynomolgus / Rhesus macaque PD-L1 Protein, Fc,Avitag (Cat. No. PD1-C82F3) captured on Protein A Chip can bind Cynomolgus PD-1 Protein, His Tag (Cat. No. PD1-C52H5) with an affinity constant of 3.09 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol
PDL-C82E8-SPR
PD-L1 SPR

Cynomolgus PD-1, Fc Tag (Cat. No. PD1-C5254) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Biotinylated Cynomolgus / Rhesus macaque PD-L1, His,Avitag (Cat. No. PDL-C82E8) with an affinity constant of 6.59 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

Customer Reviews

Synonym Name

PD-L1,CD274,B7-H1,PDCD1L1,PDCD1LG1

Background

Programmed cell death 1 ligand 1 (PD-L1) is also known as cluster of differentiation (CD274) or B7 homolog 1 (B7-H1), is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses. B7-H1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. PD-L1 is highly expressed in the heart, skeletal muscle, placenta and lung and weakly expressed in the thymus, spleen, kidney and liver. PD-L1 is expressed on activated T-cells, B-cells, dendritic cells, keratinocytes and monocytes. PD-L1 is up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation and up-regulated in B-cells activated by surface Ig cross-linking. PD-L1 involve in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Socazolimab ZKAB001; STI-A1014; STIA-1014; ZKAB-001; STI-1014 Approved Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd, Sorrento Therapeutics Inc 善克钰 Mainland China Uterine Cervical Neoplasms Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd 2023-12-19 Biliary Tract Neoplasms; Esophageal Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Osteosarcoma; Bile Duct Neoplasms; Esophageal Squamous Cell Carcinoma; Uterine Cervical Neoplasms; Melanoma Details
Envafolimab KN-035; ASC-22 Approved Suzhou Alphamab Co Ltd, 3d Medicines (Sichuan) Co Ltd ENWEIDA, 恩维达 Mainland China Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer 3d Medicines (Sichuan) Co Ltd 2021-11-25 Dermatofibrosarcoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Sarcoma; Microsatellite instability-high cancer; Colonic Neoplasms; Neoplasms; Shock, Septic; Sepsis; Esophageal Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Mismatch Repair Deficient Cancer; Hepatitis B, Chronic; Liver Neoplasms; Solid tumours; HIV Infections Details
Atezolizumab RO-5541267; 52CMI0WC3Y (UNII code); RG-7446; MPDL-3280A; RG-7446-42 Approved Genentech Inc 泰圣奇, Tecentriq United States Carcinoma, Non-Small-Cell Lung Genentech Inc 2016-05-18 Genital Neoplasms, Female; Thymoma; Lymphoma; Penile Neoplasms; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Lymphoproliferative Disorders; Oropharyngeal Neoplasms; Sezary Syndrome; Metastatic breast cancer; Colorectal Neoplasms; Urologic Neoplasms; Bile Duct Neoplasms; Peritoneal Neoplasms; Sarcoma; Lymphoma, Follicular; Urethral Neoplasms; Breast Neoplasms; Laryngeal Neoplasms; Uterine Cervical Neoplasms; Liposarcoma, Myxoid; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Melanoma; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neuroendocrine Tumors; Glioma; Endometrial Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Sarcoma, Alveolar Soft Part; Neoplasms, Unknown Primary; Urogenital Neoplasms; Lung Neoplasms; Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Anus Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Salivary Gland Neoplasm Details
Avelumab PF-06834635; MSB-0010718C Approved Merck Serono Bavencio United States Carcinoma, Merkel Cell Emd Serono Inc 2017-03-23 Lymphoma, T-Cell; Microsatellite Instability; Lymphoma, Extranodal NK-T-Cell; Peritoneal Neoplasms; Sezary Syndrome; Meningeal Neoplasms; Colorectal Neoplasms; Testicular Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Neuroendocrine; Thymoma; Carcinoma, Pancreatic Ductal; Penile Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma; Osteosarcoma; Esophageal Squamous Cell Carcinoma; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Endometrial Neoplasms; Testicular Diseases; Neoplasm Metastasis; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Meningioma; Carcinoma, Hepatocellular; Neoplasms, Germ Cell and Embryonal; Lymphoma, Large B-Cell, Diffuse; Kidney Neoplasms; Ovarian Neoplasms; Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma, Ovarian Epithelial; Skin Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Solid tumo Details
Adebrelimab SHR-1316; HTI-1088; HTI-1316 Approved Jiangsu Hengrui Medicine Co Ltd, Atridia Pty Ltd 艾瑞利 Mainland China Small Cell Lung Carcinoma Shanghai Suncadia Medicine Co Ltd 2023-02-28 Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Nasopharyngeal Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Esophageal Squamous Cell Carcinoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular Details
Durvalumab 28X28X9-OKV (UNII code); MEDI-4736 Approved Medimmune Llc 英飞凡, Imfinzi United States Carcinoma, Non-Small-Cell Lung Astrazeneca Uk Ltd 2018-02-16 Primary Myelofibrosis; Esophageal adenocarcinoma; Endometrial Neoplasms; Uterine Neoplasms; Fallopian Tube Neoplasms; Esophageal Squamous Cell Carcinoma; Gallbladder Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Pancreatic Ductal; Sezary Syndrome; Lymphoma, T-Cell, Cutaneous; Urologic Neoplasms; Oropharyngeal Neoplasms; Testicular Neoplasms; Pinealoma; Ureteral Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Microsatellite Instability; Primary mediastinal B cell lymphoma; Melanoma; Mycosis Fungoides; Neoplasms, Germ Cell and Embryonal; Laryngeal Diseases; Dysgerminoma; Neoplasm Metastasis; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Urethral Neoplasms; Carcinoma, Non-Small-Cell Lung; Laryngeal Neoplasms; Lip Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Thyroid Neoplasms; Mouth Neoplasms; Appendiceal Neoplasms Details
Sugemalimab WBP-3155; CS-1001 Approved Cstone Pharmaceuticals (Suzhou) Co Ltd 择捷美, Cejemly, ZEJIEMEI Mainland China Carcinoma, Non-Small-Cell Lung Cstone Pharmaceuticals (Suzhou) Co Ltd 2021-12-20 Urinary Bladder Neoplasms; Carcinoma, Hepatocellular; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, T-Cell; Lymphoma; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Prostatic Neoplasms; Lymphoma, Extranodal NK-T-Cell; Solid tumours; Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Hodgkin Disease; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Bintrafusp alfa M-7824; GSK-4045154; MSB-0011359C Phase 3 Clinical Merck Serono Lung Neoplasms; Sarcoma; Cholangiocarcinoma; Breast Neoplasms; Microsatellite Instability; Vulvar Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Colorectal Neoplasms; Oropharyngeal Neoplasms; Thymus Neoplasms; Gallbladder Neoplasms; Adenomyoepithelioma; Lymphoma; Brain metastases; Urogenital Neoplasms; Thymoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Sarcoma, Kaposi; Triple Negative Breast Neoplasms; Solid tumours; Hematologic Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Anus Neoplasms; Stomach Neoplasms; Carcinoma; Carcinoma, Renal Cell; Esthesioneuroblastoma, Olfactory; Biliary Tract Neoplasms; Neoplasms; Colonic Neoplasms; Small Cell Lung Carcinoma; Papillomavirus Infections; Carcinoma, Transitional Cell; Nose Neoplasms; Ganglioglioma; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms Details
Retlirafusp alfa SHR-1701 Phase 3 Clinical Jiangsu Hengrui Medicine Co Ltd Solid tumours; Esophageal Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Hodgkin Disease; Breast Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Erfonrilimab KN046; KN-046 Phase 3 Clinical Jiangsu Alphamab Biopharmaceuticals Co Ltd Colorectal Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Thymoma; Esophageal Squamous Cell Carcinoma; Lymphoma; Solid tumours; Thymus Neoplasms; Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Biliary Tract Neoplasms Details
PM-8002 PM8002; PM-8002; BNT-327 Phase 3 Clinical Biotheus Inc Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Mesothelioma; Neuroendocrine Tumors; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
PD-L1 peptide vaccine (IO Biotech) IO-103 Phase 2 Clinical Herlev Hospital, Io Biotech Aps Carcinoma, Basal Cell; Smoldering Multiple Myeloma Details
FAZ-053 FAZ-053; LAE-005; LAE005 Phase 2 Clinical Novartis Pharma Ag Solid tumours; Triple Negative Breast Neoplasms; Chordoma; Sarcoma, Alveolar Soft Part Details
MAX-10181 MAX-10181; MAX-1 Phase 2 Clinical Maxinovel Pharmaceuticals Co Ltd Solid tumours; Neoplasms Details
PD-L1 t-haNK cell therapy Phase 2 Clinical Nantkwest Inc Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Glioblastoma; Neoplasm Metastasis Details
RC-98 RC-98; RC98 Phase 2 Clinical RemeGen Co Ltd Solid tumours; Stomach Neoplasms; Neoplasms Details
Durvalumab/Gefitinib Phase 2 Clinical Medimmune Carcinoma, Non-Small-Cell Lung Details
INCB-086550 INCB-086550; INCB-86550 Phase 2 Clinical Incyte Corp Solid tumours; Carcinoma; Carcinoma, Renal Cell; Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular Details
BMS-936559 MDX-1105; BMS-936559 Phase 2 Clinical Bristol-Myers Squibb Company Leukemia, Myelogenous, Chronic; Shock, Septic; HIV Infections; Hodgkin Disease; Sepsis; Neoplasms; Small Cell Lung Carcinoma; Multiple Myeloma; Lymphoma, Non-Hodgkin; Melanoma Details
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) Phase 2 Clinical Changhai Hospital Of Shanghai Pancreatic Neoplasms Details
PM-8001 6MW3111; PM-8001 Phase 2 Clinical Biotheus Inc Solid tumours; Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
89Zr-durvalumab Phase 2 Clinical Radboud University Nijmegen Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Danburstotug STI-3031; STI-A1015; IMC-001 Phase 2 Clinical Sorrento Therapeutics Inc Solid tumours; Lymphoma, T-Cell, Peripheral; Biliary Tract Neoplasms; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Lymphoma; Bacterial Infections; Neoplasm Metastasis Details
Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology) LP-002 Phase 2 Clinical Taizhou Houde Aoke Technology Co Ltd Solid tumours; Lymphoma, B-Cell; Small Cell Lung Carcinoma; Digestive System Neoplasms; Primary mediastinal B cell lymphoma; Carcinoma, Squamous Cell; Melanoma Details
Enristomig ES101; INBRX-105 Phase 2 Clinical Inhibrx Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Thoracic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Nasopharyngeal Carcinoma; Oropharyngeal Neoplasms; Esophageal adenocarcinoma; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung Details
AP-203 AP-203; AP203 Phase 2 Clinical AP Biosciences Inc Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung Details
HB-0036 HB-0036 Phase 2 Clinical Solid tumours; Carcinoma, Non-Small-Cell Lung Details
FS 118 FS-118 Phase 2 Clinical Merck Serono, F-Star Squamous Cell Carcinoma of Head and Neck; Neoplasms; Neoplasm Metastasis Details
Acasunlimab PD-L1x4-1BB; DuoBody-PD-L1x4-1BB; GEN1046; BNT-311 Phase 2 Clinical Genmab A/S, Biontech Se Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
JSKN-033 JSKN033; JSKN-033; JSKN-003/Envafolimab Phase 2 Clinical Jiangsu Alphamab Biopharmaceuticals Co Ltd Solid tumours Details
MAX-80391 MAX-80391; MAX-8 Phase 2 Clinical Maxinovel Pharmaceuticals Co Ltd Solid tumours Details
PRS-344 PRS-344/ONC0055; PRS-344; PRS-344/S095012; PRS-344S095012; S-095012 Phase 2 Clinical Pieris Pharmaceuticals Inc, Laboratoires Servier Solid tumours Details
Pacmilimab CX-072 Phase 2 Clinical Cytomx Therapeutics Inc Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Lymphoma; Melanoma Details
BPB-101 BPB-101 Phase 2 Clinical Betta Pharmaceuticals Co Ltd Solid tumours Details
LB-101 (Centessa Pharmaceuticals) LB-101 (Centessa Pharmaceuticals); LB-101 Tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody Phase 2 Clinical Centessa Pharmaceuticals Plc Solid tumours Details
AB-001 (Agastiya Biotech) AB01 (Agastiya Biotech); AB001 (Agastiya Biotech); AB-01 (Agastiya Biotech) Phase 2 Clinical Agastiya Biotech LLC Neoplasms Details
6MW-3511 6MW-3511 Phase 2 Clinical Mabwell (Shanghai) Bioscience Co Ltd Solid tumours; Neoplasms Details
18F-BMS-986229 18F-BMS-986229; [18F]BMS-986229 Phase 2 Clinical Bristol-Myers Squibb International Corp Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma Details
sirpiglenastat DRP-104 Phase 2 Clinical Dracen Pharmaceuticals Inc Solid tumours; Fibrolamellar hepatocellular carcinoma; Carcinoma, Non-Small-Cell Lung Details
Emfizatamab GNC-038 Phase 2 Clinical SystImmune Solid tumours; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Central Nervous System Lymphoma Details
99mTc-NM-01 99mTc-NM-01 Phase 2 Clinical Nanomab Technology Ltd Carcinoma, Non-Small-Cell Lung Details
HB-0028 HB-0028 Phase 2 Clinical Shanghai Huaota Biopharmaceutical Co Ltd Solid tumours; Uterine Cervical Neoplasms Details
PM-1022 PM-1022 Phase 2 Clinical Biotheus Inc Neoplasms Details
LBL-024 LBL-024; LBL024 Phase 2 Clinical Nanjing Leads Biolabs Co Ltd Solid tumours; Neoplasms; Carcinoma, Neuroendocrine Details
IBC-0966 IBC-0966 Phase 2 Clinical SunHo (China) BioPharmaceutical Co Ltd Neoplasms Details
QLF31907 QLF31907; QLF-31907 Phase 2 Clinical Qilu Pharmaceutical Co Ltd Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Lymphoma, Non-Hodgkin; Melanoma Details
INCB-099280 INCB-099280; INCB-99280 Phase 2 Clinical Incyte Corp Ltd Nasopharyngeal Carcinoma; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; DNA Repair-Deficiency Disorders; Colorectal Neoplasms; Microsatellite Instability; Solid tumours; Mesothelioma; Microsatellite instability-high cancer; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Renal Cell Details
Nebratamig GNC-035 Phase 2 Clinical Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Metastatic breast cancer; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Carrizumab Phase 2 Clinical Jiangsu Hengrui Pharmaceutical Co Ltd Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma Details
Recombinant anti-PD-L1/TGF-β bispecific antibody Y101D; Y-101D Phase 2 Clinical Wuhan Yzy Biopharma Co Ltd Solid tumours; Pancreatic Neoplasms; Carcinoma, Hepatocellular; Adenocarcinoma Details
6MW-3211 6MW3211; 6MW-3211 Phase 2 Clinical Mabwell (Shanghai) Bioscience Co Ltd Carcinoma, Renal Cell; Myelodysplastic Syndromes; Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma Details
ADG-104 ADG-104; ADG104 Phase 2 Clinical Guilin Sanjin Pharmaceutical Co Ltd, Adagene Inc Neoplasms Details
Q-1802 Q-1802 Phase 2 Clinical Qiyu Biotechnology (Shanghai) Co Ltd Solid tumours; Esophageal Neoplasms; Gastrointestinal Neoplasms Details
HLX-301 HLX-301 Phase 2 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
TQB-2858 TQB-2858 Phase 2 Clinical Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group Neoplasms; Pancreatic Neoplasms; Nasopharyngeal Neoplasms; Sarcoma; Endometrial Neoplasms; Uterine Cervical Neoplasms Details
Sotiburafusp alfa HB0025; HB-0025 Phase 2 Clinical Shanghai Huaota Biopharmaceutical Co Ltd Hematologic Neoplasms; Solid tumours; Kidney Neoplasms; Carcinoma, Renal Cell; Endometrial Neoplasms; Carcinoma, Hepatocellular Details
PD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital) Phase 2 Clinical Shanghai Zhongshan Hospital Cholangiocarcinoma Details
HL-301 HL-301 Phase 2 Clinical Hanlim Pharm Co Ltd Radiation Pneumonitis; Small Cell Lung Carcinoma; Lung Neoplasms Details
IMM-2510 IMM-2510 Phase 2 Clinical ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Solid tumours; Sarcoma Details
PM-1003 PM1003 Phase 2 Clinical Biotheus Inc Solid tumours Details
Lesabelimab BC-003 Phase 2 Clinical Guilin Sanjin Pharmaceutical Co Ltd, Adagene (Suzhou) Ltd, Dragonboat Biopharmaceutical, Baifan Biotechnology (Shanghai) Co Ltd Carcinoma, Renal Cell; Neoplasms; Urinary Bladder Neoplasms; Penile Neoplasms Details
Emdifen Phase 1 Clinical Tianjin Chase Sun Pharmaceutical Co Ltd, Chinese Academy Of Medical Sciences Solid tumours Details
89Zr-DFO-Atezolizumab 89Zr-DFO-Atezolizumab Phase 1 Clinical The University Of Texas Southwestern Medical Center Carcinoma, Renal Cell; Diagnostic agents Details
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs Phase 1 Clinical Hunan Zhaotai Yongren Biotech Co Ltd Carcinoma, Non-Small-Cell Lung Details
Lodapolimab LY-3300054 Phase 1 Clinical Eli Lilly And Company Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
SL-279252 TAK-252; SL-279252 Phase 1 Clinical Takeda Pharmaceutical Co Ltd, Shattuck Labs Inc Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma Details
LOR-S03 CDX-527 Phase 1 Clinical Celldex Therapeutics Ovarian Neoplasms; Solid tumours; Liver Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Neoplasms; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung Details
MCLA-145 MCLA-145 Phase 1 Clinical Incyte Corp, Merus Nv Solid tumours; Lymphoma, B-Cell; Neoplasms Details
CAR-T cell therapy (Timmune Biotech) Phase 1 Clinical Tianjin Timmune Biotech Inc Multiple Myeloma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Opucolimab HLX-20 Phase 1 Clinical Shanghai Henlius Biotech Inc Solid tumours; Neoplasms Details
INCB-099318 INCB-099318; INCB-99318 Phase 1 Clinical Incyte Corp Neoplasms; Uterine Cervical Neoplasms; Penile Neoplasms; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Nasopharyngeal Carcinoma; Mesothelioma; Microsatellite instability-high cancer; Solid tumours; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Anus Neoplasms; Carcinoma, Merkel Cell; Ovarian Neoplasms Details
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) Phase 1 Clinical Tianjin Mycure Medical Technology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
RG-6084 RG-6084; RO-7191863 Phase 1 Clinical F. Hoffmann-La Roche Ltd Hepatitis B Details
IMMH-010 IMMH-010 Phase 1 Clinical Tianjin Chase Sun Pharmaceutical Co Ltd Solid tumours; Neoplasms Details
Betifisolimab MSB-2311 Phase 1 Clinical Mabspace Biomedicine (Suzhou) Co Ltd Solid tumours Details
Simridarlimab IBI-322; IBI322 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Hematologic Neoplasms; Solid tumours; Bone Marrow Neoplasms; Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, T-Cell Details
AB-101 (Arbutus Biopharma) AB-101 (Arbutus Biopharma) Phase 1 Clinical Arbutus Biopharma Corp Hepatitis B Details
HLX-43 HLX-43; HLX43 Phase 1 Clinical Shanghai Henlius Biotech Inc Solid tumours Details
SIM-0237 SIM-0237 Phase 1 Clinical Simcere Pharmaceutical Group Ltd Solid tumours; Urinary Bladder Neoplasms Details
LP-008 LP-008 Phase 1 Clinical Solid tumours Details
EMB-09 EMB-09 Phase 1 Clinical Shanghai Epimab Biotherapeutics, Inc Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
CYTO-102 CYTO-NK-102; CYTO-102; COH06 Phase 1 Clinical CytoImmune Therapeutics Inc Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
TS-1905 TS-1905; LY-01019; BA-1201 Phase 1 Clinical Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Papillomavirus Infections; Carcinoma, Non-Small-Cell Lung Details
BH-3120 BH-3120 Phase 1 Clinical Hanmi Pharmaceutical Co Ltd Solid tumours Details
Xirestomig ATG-101; ATG101; YN051 Phase 1 Clinical The Origin Cell Technology Group Co Ltd Solid tumours; Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neoplasm Metastasis Details
QL-301 QL-301 Phase 1 Clinical Qlsf Biotherapeutics Inc Neoplasms Details
MVR-C5252 C-5252; MVR-C5252 Phase 1 Clinical Immvira Co Ltd Solid tumours; Ganglioglioma; Glioblastoma; Brain Neoplasms; Glioma Details
Q-1801 Q-1801; Q 1801 Phase 1 Clinical Qiyu Biotechnology (Shanghai) Co Ltd Solid tumours Details
IMGS-001 IMGS-001 Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms Details
ABL-501 ABL-501 Phase 1 Clinical Abl Bio Inc Solid tumours Details
CTX-8371 CTX-8371 Phase 1 Clinical Compass Therapeutics LLC Solid tumours; Squamous Cell Carcinoma of Head and Neck; Hodgkin Disease; Triple Negative Breast Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
IBC-Ab002 IBC-Ab002 Phase 1 Clinical ImmunoBrain Checkpoint Inc Alzheimer Disease Details
Pd-1-pik Pd-1-pik Phase 1 Clinical Huashan Hospital Affiliated To Fudan University Glioblastoma Details
Reozalimab IBI-318; LY-3434172; LY3434172 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular Details
LW-347 LW-347 Phase 1 Clinical Shanghai Longwood Biopharmaceuticals Co Ltd Neoplasms Details
A-337 (Klus Pharma) A337 (Klus Pharma); A-337 (Klus Pharma) Phase 1 Clinical Klus Pharma Inc Neoplasms Details
PMI-06 PMI06; PMI-06 Phase 1 Clinical Precision Molecular Inc Carcinoma, Non-Small-Cell Lung Details
YL-222 YL222; YL-222 Phase 1 Clinical MediLink Therapeutics Co Ltd Solid tumours Details
ND-021 ND-021; NM21-1480; CS-2006; CS2006 Phase 1 Clinical Numab Therapeutics Ag, Cstone Pharmaceuticals Solid tumours; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details
SPX-303 SPX-303 Phase 1 Clinical SparX Biopharmaceutical Corp Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck Details
KM602 KM602; KM-602; XZP-KM602 Phase 1 Clinical Xuanzhu (Shijiazhuang) Biotechnology Co Ltd Solid tumours Details
B-901 B-901; B901 Phase 1 Clinical FutureGen Biopharm (Beijing) Co Ltd Solid tumours Details
Recombinant anti-PD-L1/TGF-β bifunctional fusion protein Phase 1 Clinical Hualan Genetic Engineering (Henan) Co Ltd Solid tumours Details
AUR-106 AUR-106 Phase 1 Clinical Aurigene Discovery Technologies Ltd Kidney Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
89Zr-S095012 89Zr-S-095012 Phase 1 Clinical Institut De Recherches Internationales Servier Solid tumours Details
RAD-204 RAD-204; 177Lu-RAD204 Phase 1 Clinical Radiopharm Theranostics Ltd Carcinoma, Non-Small-Cell Lung Details
RAD-203 RAD-203 Phase 1 Clinical Radiopharm Theranostics Ltd Carcinoma, Non-Small-Cell Lung Details
HK-010 HK-010; HK010 Phase 1 Clinical Anhui Anke Biotechnology (Group) Co Ltd, Hefei Hankemab Biotechnology Co Ltd Neoplasms Details
Dual-targeting VEGFR1 and PD-L1 CAR-T cells Therapy (Sichuan University) Phase 1 Clinical Sichuan University Serositis; Ascites Details
Ori-Bs-001 Ori-Bs-001 Phase 1 Clinical OriCell Therapeutics Co Ltd Solid tumours Details
BC008-1A BC008-1A Phase 1 Clinical Sichuan Luzhou Buchang Biopharmaceutical Co Ltd Solid tumours Details
B-1962 B1962; AP-505 Phase 1 Clinical AP Biosciences Inc Solid tumours; Liver Neoplasms; Neoplasms; Lung Neoplasms Details
LB-1410 LB-1410 Phase 1 Clinical L&L Biopharma Co Ltd Solid tumours; Neoplasms; Lymphoma Details
HBM-9027 HBM-9027; HBM9027 Phase 1 Clinical Harbour Biomed Solid tumours; Neoplasms Details
QL-415 QL-415 Phase 1 Clinical Qlsf Biotherapeutics Inc Neoplasms Details
SGN-PDL1V SGN-PDL1V Phase 1 Clinical Ovarian Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
ASC-61 ASC-61 Phase 1 Clinical Ascletis Pharma Inc Solid tumours; Neoplasms Details
DR-30206 DR-30206 Phase 1 Clinical Zhejiang Doer Biologics Corp Solid tumours Details
BPI-371153 BPI-371153 Phase 1 Clinical Betta Pharmaceuticals Co Ltd Solid tumours; Liver Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung Details
CS-23546 CS-23546; CS23546 Phase 1 Clinical Shenzhen Chipscreen Biosciences Co Ltd Neoplasms; Immune System Diseases Details
SG-1408 SG-1408; SG1408 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Solid tumours Details
CHECKvacc CF33-hNIS-antiPDL1 Phase 1 Clinical Imugene Ltd, City Of Hope National Medical Center Triple Negative Breast Neoplasms; Breast Neoplasms; Metastatic breast cancer Details
706-3SBio SSGJ-706; 706 anti -PD1/PD -L1 BsAb; 706 anti-PD1/PD-L1 Bispecific antibody Phase 1 Clinical 3sbio Inc Solid tumours; Composite Lymphoma; Lymphoma Details
Gallium [68Ga] Natan recombinant PD-L1 single domain antibody SNA-002; 68Ga-NOTA-SNA002 Phase 1 Clinical Smartnuclide Biopharma Solid tumours; Neoplasms; Contrast agents Details
SHS-009 SHS-009; SH009; SH-009 Phase 1 Clinical Nanjing Sanhome Pharmaceutical Co Ltd Neoplasms Details
SHS-006(Nanjing Sanhome Pharmaceutical) SHS-006; SH-006; SH006 Phase 1 Clinical Nanjing Sanhome Pharmaceutical Co Ltd Solid tumours Details
CN-202 CN-202 Phase 1 Clinical Curon Biopharmaceutical Ltd Hematologic Neoplasms; Solid tumours; Neoplasm Metastasis Details
Recombinant oncolytic type II herpes simplex virus (Binhui Biopharmaceutical) BS-006; oHSV2-BiTEs Phase 1 Clinical Wuhan Binhui Biotechnology Co Ltd Solid tumours; Neoplasms; Melanoma; Uterine Cervical Neoplasms Details
FS-222 FS-222 Phase 1 Clinical F-star Beta Ltd Neoplasms; Neoplasm Metastasis Details
IMM-2520 IMM-2520 Phase 1 Clinical ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
BAT-7104 BAT-7104 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours; Neoplasms Details
CA-170 CA-170; AUPM-170 Phase 1 Clinical Aurigene Solid tumours Details
FH-2001 FH-2001 Phase 1 Clinical Shanghai Fosun Pharmaceutical Industrial Development Co Ltd Solid tumours Details
TT-00420/Atezolizumab Phase 1 Clinical TransThera Sciences (Nanjing) Inc Gastrointestinal Neoplasms Details
PF-07257876 Phase 1 Clinical Pfizer Inc Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung Details
AN-4005 AN-4005 Phase 1 Clinical Hangzhou Adlai Nortye Biopharma Co Ltd Solid tumours; Neoplasms; Lymphoma Details
BR-102 BR102 Phase 1 Clinical BioRay Pharmaceutical Co Ltd Solid tumours; Neoplasms Details
TST-005 TST-005; TST005 Phase 1 Clinical Mabspace Biomedicine (Suzhou) Co Ltd Solid tumours; Neoplasms; Papillomavirus Infections Details
GT-90008 GS-19-PLB-1C; GT-90008; GS-19 Phase 1 Clinical Suzhou Koshine Biomedica Inc Solid tumours Details
TJ-L14B ABL-503; TJ-L14B/ABL503; ABL503 Phase 1 Clinical I-Mab Biopharma Co Ltd Solid tumours Details
CCX-559 CCX-559 Phase 1 Clinical Chemocentryx Inc Solid tumours; Neoplasms Details
Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) Phase 1 Clinical Sichuan University Peritoneal Neoplasms; Pleural Effusion, Malignant Details
QLS31901 QLS-31901; QLS31901 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Neoplasms Details
IMM2505 IMM2505; IMM-2505 Phase 1 Clinical SunHo (China) BioPharmaceutical Co Ltd, ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Solid tumours Details
SKB-337 SKB337; A-337; SKB-337 Phase 1 Clinical Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Solid tumours Details
GNC-039 GNC-039 Phase 1 Clinical Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis Details
ABSK-043 ABSK043 Phase 1 Clinical ABbisko Therapeutics Co Ltd Solid tumours; Neoplasms Details
IBI-323(Innovent Biologics) IBI-323 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
KN-052 KN-052 Phase 1 Clinical Suzhou Alphamab Co Ltd Solid tumours Details
SG12473 SG12473; SG-12473 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Hematologic Neoplasms; Solid tumours; Neoplasms Details
BJ-005 BJ-005 Phase 1 Clinical Boji Biomedical Technology (Hangzhou) Co Ltd Solid tumours; Lymphoma Details
MT-6402 MT-6402; MT-64-6402 Phase 1 Clinical Molecular Templates Inc Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung Details
FPT-155 CD80-Fc; FPT-155 Phase 1 Clinical Five Prime Therapeutics Inc Solid tumours Details
Garivulimab BGB-A333 Phase 1 Clinical Beigene Ltd Solid tumours; Neoplasms Details
Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu) Phase 1 Clinical Jiangsu Huaiyu Pharmaceutical Co Ltd Solid tumours Details
Durvalumab/Selumetinib sulfate Phase 1 Clinical Astrazeneca Plc Neoplasms Details
18F-BMS-986192 BMS-986192-[18F] Clinical Bristol-Myers Squibb Company Neoplasms Details
89Zr-KN035（Wuxi No. 4 People's Hospital） Clinical Wuxi No. 4 People Solid tumours Details

This web search service is supported by Google Inc.

totop
Call us
Call us

Germany+49 800 0826645

United Kingdom+44 808 281 3436

Netherlands+31 800 0224992

Switzerland+41 800 040 012

France+33 800 90 78 85

Sweden+46 20 12 76 94

Denmark+45 80 83 07 62

Belgium+32 800 27 125

Email
E-Mail
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland
linkedin twitter facebook youtube

Nachricht schicken

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap